Pharming Group N.V. (PHAR) Q4 2025 Earnings — Miss Estimates

Screener

Reported March 12, 2026 · Before market open

Revenue$106.5MMiss by $5.3M

EPS$0.07Miss by $0.08

Revenue estimate$111.8M

EPS estimate$0.15

Next report

Nov 5, 2026 (in 3 months)

Revenue estimate$106.1M

EPS estimate$0.10

Versus estimates

Revenue

Q2 2026$90.2MMiss by $9.3M Q1 2026$72.4MMiss by $19.6M

Q4 2025$106.5MMiss by $5.3M

Q3 2025$97.3MMiss by $932.8K Q2 2025$110.6MBeat by $30.4M Q1 2025$86.7MBeat by $14.0M

Diluted EPS

Q2 2026$0.02Miss by $0.04 Q1 2026-$0.07Miss by $0.12

Q4 2025$0.07Miss by $0.08

Q3 2025$0.10Beat by $0.05 Q2 2025$0.06Beat by $0.16 Q1 2025-$0.22Beat by $0.03

FAQ

When did Pharming Group N.V. report Q4 2025 earnings?: Pharming Group N.V. (PHAR) reported Q4 2025 earnings on March 12, 2026 before market open.
What were Pharming Group N.V.'s Q4 2025 revenue and EPS?: Pharming Group N.V. reported revenue of $106.5M and eps of $0.07 for Q4 2025.
Did Pharming Group N.V. beat estimates in Q4 2025?: Revenue missed the consensus estimate of $111.8M by $5.3M. EPS missed the consensus estimate of $0.15 by $0.08.
How did Pharming Group N.V.'s Q4 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 11.0% from $96.0M a year earlier and eps grew 40.0% from $0.05.

Ask the moment Pharming Group N.V. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk